Future of IR Review Series

Multicenter Phase II Clinical Trial of Sorafenib Combined with TACE for Advanced Stage HCC (STAB Study)

PURPOSE To evaluate the safety and efficacy of combination therapy (TACE+ sorafenib) in patients with advanced stage HCC. STUDY DESIGN Open-label, non-randomized, single-arm multicenter phase II clinical trial. The primary endpoint was defined as the rate of completion of the treatment protocol (i.e., 2 months duration of sorafenib following TACE); Read more…

Future of IR Review Series

Multicenter Phase II Clinical Trial of Sorafenib Combined with TACE for Advanced Stage HCC (STAB Study)

PURPOSE To evaluate the safety and efficacy of combination therapy (TACE + sorafenib) in patients with advanced stage HCC. STUDY DESIGN Open-label, non-randomized, single-arm multicenter phase II clinical trial. The primary endpoint was defined as the rate of completion of the treatment protocol (i.e., 2 months duration of sorafenib following Read more…